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Abstract— Left  ventricular assist devices (LVADs) can 
provide mechanical support for a failing heart as bridge to 
transplant and destination therapy. Physiological control 
systems for LVADs should be designed to respond to changes 
in hemodynamic across a variety of clinical scenarios and 
patients by automatically adjusting the heart pump speed. In 
this study, a novel adaptive physiological control system for an 
implantable heart pump was developed to respond to 
interpatient and intrapatient variations to maintain the left-
ventricle-end-diastolic-pressure (LVEDP) in the normal range 
of 3 to 15 mmHg to prevent ventricle suction and pulmonary 
congestion. A new algorithm was also developed to detect 
LVEDP from pressure sensor measurement in real-time mode. 
Model free adaptive control (MFAC) was employed to control 
the pump speed via simulation of 100 different patient 
conditions in each of six different patient scenarios, and 
compared to standard PID control. Controller performance was 
tracked using the sum of the absolute error (SAE) between the 
desired and measured LVEDP. The lower SAE on control 
tracking performance means the measured LVEDP follows the 
desired LVEDP faster and with less amplitude oscillations 
preventing ventricle suction and pulmonary congestion (mean 
and standard deviation of SAE(mmHg) for all 600 simulations 
were 18813±29345 and 24794±28380 corresponding to MFAC 
and PID controller respectively). In four out of six patient 
scenarios, MFAC control tracking performance was better than 
the PID controller. This study shows the control performance 
can be guaranteed across different patients and conditions when 
using MFAC over PID control, which is a step towards clinical 
acceptance of these systems. 
 
    Index Terms— Left ventricular assist devices, LVEDP 
detection, model free adaptive control, physiological control, 
interpatient and intrapatient variations. 
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I. INTRODUCTION 
EFT ventricular assist devices (LVADs), which are 
mechanical pumps implanted in patients with heart failure, 
have been used as a mechanical circulatory support to assist a 
failing left ventricle during bridge to transplant, bridge to 
recovery and destination therapy [1]. Operating LVADs at 
constant speed may lead to ventricular suction (ventricular 
collapse due to low pressure in the ventricle) or pulmonary 
congestion (a condition caused by excess fluid in the lungs due 
to high pressure in the ventricle). Ventricular suction may lead 
to hemolysis, heart tissue damage near the pump inlet, right 
ventricular dysfunction or release of ventricular thrombus and 
subsequent stroke, while pulmonary congestion may lead to 
flooding of the lungs (pulmonary edema) and shortness of 
breath [2]–[4].  
To prevent these hazardous events, physiological control 
systems for LVADs can be used to automatically adjust pump 
speed in response to changes in hemodynamic or pump 
variables to satisfy control objective(s). These objectives may 
include a constant differential pressure [5], a constant pump 
inlet pressure [6], a constant pump flow [7] and a Starling-like 
controller which sets target flow rate based on the left 
ventricular end-diastolic pressure (LVEDP) [8]–[12]. Most 
investigators have previously employed proportional-integral-
derivative (PID) controller, with fixed gains, to implement 
these physiological control systems [10]–[13].  
These systems are commonly evaluated using computer 
simulations. However, in most of these simulations, [10]–[15] , 
only a single patient and/or condition is simulated. This is not 
clinically representative of the wider interpatient and 
intrapatient variations in cardiovascular system (CVS) 
dynamics. The control system, usually PID control, is tuned to 
provide optimal performance only for this specific patient and 
condition. The consequence of this is that control performance 
cannot be guaranteed across different patients and conditions, 
which may lead to more hazardous events like suction and 
congestion.  
An adaptive control system can adjust its parameters in the 
face of disturbances and time-varying plants. Adaptive control 
can be beneficial for controlling VADs because of the time- 
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varying nature of the CVS. In a recent study, a neural predictive  
controller, which is one kind of adaptive controller, was 
employed to control dual rotary blood VADs by using a trained   
Artificial Neural Network (ANN) [15], and it was shown to 
have improvements over non-adaptive control. However, ANN 
controllers need training data which is difficult and time-
consuming to collect. Furthermore, ANN controllers have a 
heavy computational burden which is not ideal from a practical 
viewpoint. Other non-linear adaptive controllers, such as fuzzy 
logic control (FLC), require the determination of rulesets which 
can be time consuming to produce and result in inefficient 
performance due to the non-linear behaviour [16], [17].   
To address these issues, we propose the use of model free 
adaptive control (MFAC) to implement physiological control 
systems for rotary LVADs. MFAC does not require the training 
process like an ANN controller, nor does it require knowledge 
about the dynamic and structural information of the controlled 
system. It only uses the real-time measurement data of the 
controlled system, resulting in a generic controller for a class of 
industrial practical systems and leading to more efficient 
control. Furthermore, unlike the FLC, MFAC also does not 
require any rules, which makes it much easier to implement.   
This study aims to develop an adaptive physiological controller 
that utilizes MFAC for an implantable LVAD that provides 
consistent control system performance across a range of 
interpatient and intrapatient variations. The objective of this 
controller is to minimize the error between the desired and   
measured LVEDP, and reduce the risk of hazardous events such 
as ventricle suction and pulmonary congestion. 
In the fo llowing sections, first the numerical model of the 
human CVS and heart pump adopted for the evaluation of the 
proposed physiological control method is introduced. Then, a 
novel method for detecting LVEDP robust to noise is presented. 
Afterwards, the MFAC is described. Then different patient 
conditions and scenarios used for evaluation of the MFAC are 
described. Subsequently, the sensitivity analysis (used to 
identify parameters from the CVS that most likely contribute to 
control performance variation) is then described. Then, the 
result of the sim ulations with interpatient and intrapatient 
variations is presented. Finally, a discussion according to the 
simulation results, limitations of the study and future works is 
presented.  
II. METHODOLOGY 
Fig. 1 shows the block diagram of the control system and 
testing methodology used in this study. It consists of four major 
blocks: Numerical model of the cardiovascular system, LVEDP 
detection, MFAC system and evaluation using different patient 
conditions and scenarios. All are described in this section as 
follows.  
A. Numerical Model of Cardiovascular System 
In this study, the simulations to investigate the 
implementation of the proposed LVEDP detection and MFAC 
(b) 
Fig. 2. Electrical equivalent circuit analogue of cardiovascular with heart–
pump interaction model. P, pressures; R, resistances; E, elastances 
(=1/compliances); L, inertances; D, diodes. The model consists of two main 
components: (1) the cardiovascular model includes left heart, systemic 
circulation, right heart, pulmonary circulation (la, left atrium; lv, left 
ventricle, ao, aorta; sa, systemic peripheral vessels, including the arteries and 
capillaries; sv, systemic veins, including small and large veins; vc, vena cava; 
ra, right atrium; rv, right ventricle; pa, pulmonary peripheral vessels, 
including pulmonary arteries and capillaries; pu, pulmonary veins and (2) 
heart-pump model includes the LVAD and RVAD, (Rin and Rout , inlet and 
outlet cannulae resistances; Lin and Lout, inlet and outlet cannulae inertances; 
Rlsuc, left suction resistance, Rrsuc, right suction resistance, Rband, banding 
resistance). The intrathoracic pressure, Pthor was assigned –4 mmHg during 
closed-chest simulated conditions [15], [18]. 
(a) 
Fig. 1. Block diagram of developed methodology 
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Fig. 3. Real-time LVEDP detection, (a) left ventricle pressure (LVP) in 
transition from rest to exercise for patient 1 with white noise variance of 2 
mmHg, (b) zoomed LVP. 
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controller, implemented in Simulink (MathWorks, Natick, MA, 
USA), were carried out on the numerical model of the 
cardiovascular system developed by Lim et al. [18] (Fig. 2). The 
model was derived based on first principles and includes left 
and right hearts, systemic and pulmonary circulations, two heart 
pump models (LVAD and RVAD) and inlet and outlet 
cannulae. The CVS and heart pump model have been validated 
using in-vitro mock-loop tests and in-vivo animal experiments 
[18]–[20].  
The VentrAssistTM centrifugal pump was used as the LVAD 
in this study (Ventracor Ltd., Sydney, Australia). The 
VentrAssist model used was based on the model provided in 
[19]–[21]. The speed range of the pump model was constrained 
between 1800 and 3000 rpm,  the clinical operating range of the 
device.   
B. Real-time LVEDP Detection 
As there is no method of LVEDP detection from LVP 
measurement in the literature, a real-time LVEDP detection 
method is described in this section. In this control system, 
LVEDP was used as the feedback variable because of its 
excellent performance in previous physiological control studies 
[13]. It is an important clinical variable indicative of ventricular 
performance and can identify clinical symptoms of heart failure 
in patients. It also has a much simpler feedback pathway than 
more complex Frank-Starling control systems. However, it is 
difficult to determine LVEDP accurately from pressure sensor 
measurement in real time due to sensor noise and a lack of ECG 
signal to trigger LVEDP identification. To address this, we 
developed a novel LVEDP detection method that has 9 steps:  
1. Smoothing the left ventricle pressure using a 
Butterworth low-pass filter with pass frequency of 5 
Hz and stop frequency of 20 Hz named as filtered LVP 
(FLVP). 
2. Computing the slope of the FLVP (SFLVP). 
3. Computing heart beat based on the finding the time 
difference between two consecutive peaks from 
SFLVP.  
4. Computing the mean of SFLVP within the last 
window of 10 samples (MSFLVP). 
5. Finding the points which meet FLVP ≥ α MSFLVP 
6. Computing an adaptive threshold (TH) equal to the 
mean of 15 highest values in the SFLVP from previous 
cardiac cycle to current time, multiplied by β. 
7. Finding the first point meeting the step 5 and 6 at the 
same time (LVEDP detection time). 
8. Finding the closest point between the local minimum 
of the SFLVP and the LVEDP detection time found in 
step 7 (LVEDP actual time). 
9. Computing the LVEDP from FLVP at LVEDP actual 
time found in step 8. 
where α and β were scaling factors, empirically adjusted to give 
a latency of 30 ms and sum of the absolute error of 1.2 mmHg 
when a noise signal with variance of 4 mmHg was added to the 
left ventricular pressure. 
Fig. 3 (a) shows the LVP in transition from rest to exercise 
for a simulated patient with white noise variance of 2 mmHg.  
Fig. 3 (b) depicts the original LVP, LVP with added noise, 
filtered LVP (FLVP), slope of the FLVP (SFLVP), identified  
TABLE I 
NORMAL VALUES AND DESCRIPTION OF CARDIOVASCULAR MODEL 
PARAMETERS FOR INTERPATIENT AND INTRAPATIENT SIMULATIONS    
No Parameter (unit) Description Normal Value 
1 Eeslvf (mmHg.mL-1) LV end systolic elastance 3.54 
2 Eesrvf (mmHg.mL-1) RV end systolic elastance 1.75 
3 Eao (mmHg.mL-1) Aortic elastance 1.04 
4 Eesla (mmHg.mL-1) LA end systolic elastance 0.2 
5 Eesra (mmHg.mL-1) RA end systolic elastance 0.2 
6 Epa (mmHg.mL-1) Pulmonary arterial elastance 0.15 
7 Epu (mmHg.mL-1) Pulmonary vein elastance 0.04 
8 Esa (mmHg.mL-1) Systemic arterial elastance 0.37 
9 Esv (mmHg.mL-1) Systemic vein elastance 0.013 
10 Evc (mmHg.mL-1) Vena cava elastance 0.03 
11 Rao (mmHg.s.mL-1) Aortic resistance 0.2 
12 Rra (mmHg.s.mL-1) Right atrium resistance 0.012 
13 Rpv (mmHg.s.mL-1) Pulmonary valve resistance 0.02 
14 Rsv (mmHg.s.mL-1) Systemic venous resistance 0.12 
15 Tc (s) Heart rate coefficient 1 
16 Tsys0 (s) Maximum systolic heart period 0.5 
17 V0la (mL) LA end diastolic volume at zero pressure 20 
18 V0lvf (mL) LV end diastolic volume at zero pressure 40 
19 V0ra (mL) RA end diastolic volume at zero pressure 20 
20 V0rvf (mL) RV end diastolic volume at zero pressure 50 
21 Vdla (mL) LA end systolic volume at zero pressure 10 
22 Vdlvf (mL) LV end systolic volume at zero pressure 16.77 
23 Vdra (mL) RA end systolic volume at zero pressure 10 
24 Vdrvf (mL) RV end systolic volume at zero pressure 40 
25 Rmt (mmHg.s.mL-1) Mitral valve resistance 0.01 
26 Rav (mmHg.s.mL-1) Aortic valve resistance 0.02 
27 Vuao (mL) Aortic unstressed volume 230.88 
28 Vupa (mL) Pulmonary arterial unstressed volume 91.67 
29 Vupu (mL) Pulmonary vein unstressed volume 132.39 
30 Vusa (mL) Systemic arterial unstressed volume 231.04 
31 Vusv (mL) Systemic vein unstressed volume 1976.1 
32 Vuvc (mL) Vena cava unstressed volume 136.17 
33 P0la (mmHg) LA end diastolic stiffness scaling term 0.5 
34 P0lvf (mmHg) LV end diastolic stiffness scaling term 0.98 
35 P0ra (mmHg) RA end diastolic stiffness scaling term 0.5 
36 P0rvf (mmHg) RV end diastolic stiffness scaling term 0.91 
37 Vtotal (mL) Total blood volume 5200 
38 λla (mL-1) LA end diastolic stiffness coefficient 0.025 
39 λlvf (mL-1) LV end diastolic stiffness coefficient 0.028 
40 λra (mL-1) RA end diastolic stiffness coefficient 0.025 
41 λrvf (mL-1) RV end diastolic stiffness coefficient 0.028 
42 Lao (mmHg.s2.ml-2) Aortic inertance 0.0001 
43 Lpa (mmHg.s2.ml-2) Pulmonary arterial inertance 7.70e-05 
Fig. 4. A sample simulation for comparison of MFAC and PID in transition 
from rest to exercise for patient 45. 
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LVEDP and latency between LVEDP detection time and 
LVEDP actual time. As it can be seen in the Fig. 3 (b), the green 
point shows the exact location of LVEDP before ventricle 
contraction. The sampling rate of measured variables is 200 Hz. 
The LVEDP detection method was evaluated in six different 
patient scenarios; rising and falling pulmonary vascular 
resistance (PVR), rising and falling systemic vascular 
resistance (SVR), rest to exercise and postural change with 100 
different patient conditions in each. To vary the SVR and PVR 
in the model, systemic arterial resistance (Rsa) and pulmonary 
arterial resistance (Rpa) were changed, as arterial resistance is 
the main contributor to total vascular resistance in the numerical 
model. In order to evaluate the impact of the pressure sensor 
noise on the developed LVEDP detection, a white noise signal 
with different levels of variance (0 to 4) was added to the left 
ventricular pressure. Mean of absolute error between LVEDP 
detection and actual time is defined by (1): 
𝑀𝐴𝐸 ൌ 1𝑛 ෍|𝐿𝑉𝐸𝐷𝑃 𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒௜ െ  𝐿𝑉𝐸𝐷𝑃 𝑎𝑐𝑡𝑢𝑎𝑙 𝑡𝑖𝑚𝑒௜|
௡
௜ୀଵ
 
  ሺ1ሻ 
where MAE is the mean of the absolute error (millisecond), 
LVEDP detection timei and LVEDP actual timei are detection 
and real locations (time) of the LVEDP derived from the left 
ventricle pressure and n is the number of total samples in each 
simulation which equals to the number of cardiac cycles in each 
scenario calculated by LVEDP detection method. 
C. Model Free Adaptive Control (MFAC) 
The MFAC is an adaptive control system which does not 
need the model of the plant to design the controller. It is 
designed by using the input/output measurement data of the 
controlled plant, without knowledge of the system structure or 
dynamics information of the controlled plant explicitly or 
implicitly. Specifically, MFAC identifies the linear or nonlinear 
model of the plant via a series of equivalent dynamic 
linearization data models within dynamic operation points of 
the closed-loop system by using a dynamic linearization 
technique (DLT) and pseudo-partial derivative (PPD) [16], 
[17]. A brief description of the MFAC follows.  
A single input, single output (SISO) nonlinear discrete-time 
system can be defined as follows: 
 
𝑦ሺ𝑘 ൅ 1ሻ ൌ 𝑓ሺ𝑦ሺ𝑘ሻ, … , 𝑦൫𝑘 െ 𝑛௬൯, 𝑢ሺ𝑘ሻ, … , 𝑢ሺ𝑘 െ 𝑛௨ሻሻ 
  ሺ2ሻ 
 
where 𝑦ሺ𝑘ሻ 𝜖 𝑅 and 𝑢ሺ𝑘ሻ 𝜖 𝑅 are the system output and control 
input at time 𝑘, 𝑛௬ and 𝑛௨ are unknown orders of output and 
input, and 𝑓ሺ… ሻ 𝜖 𝑅 is the unknown nonlinear function [16]. 
 The compact form dynamic linearization of nonlinear system 
(2) can be defined by (3):   
 
 𝑦ሺ𝑘 ൅ 1ሻ ൌ 𝑦ሺ𝑘ሻ ൅ 𝜑ሺ𝑘ሻ ∆𝑢ሺ𝑘ሻ ሺ3ሻ 
 
where 𝜑ሺ𝑘ሻ is called pseudo-partial derivative (PPD). 
 In order to find the control input uሺkሻ, it is considered to 
minimize the following equation to have less error (difference 
between the desired and system output) and changes of two 
consecutive control inputs:    
𝐽൫𝑢ሺ𝑘ሻ൯ ൌ ‖𝑦∗ሺ𝑘 ൅ 1ሻ െ 𝑦ሺ𝑘 ൅ 1ሻ‖ଶ ൅ 𝜆 ‖𝑢ሺ𝑘ሻ െ 𝑢ሺ𝑘 െ 1ሻ‖ଶ 
  ሺ4ሻ 
 
where 𝑦∗ሺ𝑘 ൅ 1ሻ and 𝜆 are desired output and a weighting 
constant respectively [16]. 
  By substituting (3) into (4) and differentiating (4) with 
respect to 𝑢ሺ𝑘ሻ equals to zero, the control input is as follows:  
 
 
 
𝑢ሺ𝑘ሻ ൌ 𝑢ሺ𝑘 െ 1ሻ ൅  𝜌 𝜑ሺ𝑘ሻ ሺ𝑦
∗ሺ𝑘 ൅ 1ሻ െ 𝑦ሺ𝑘ሻሻ
𝜆 ൅ ‖ 𝜑ሺ𝑘ሻ‖ଶ  ሺ5ሻ 
where 𝜌 is a step constant which is added to make (5) more 
general and flexible.  
 As the unknown PPD parameter 𝜑ሺ𝑘ሻ is time-varying, the 
least squares algorithm cannot track it well. Therefore, a time-
varying estimation algorithm is used to estimate PPD 𝜑ሺ𝑘ሻ. By 
using the modified projection algorithm, the estimated 
unknown PPD 𝜑ሺ𝑘ሻ can be found as follows [22]: 
The objective function for 𝜑ሺ𝑘ሻ estimation is defined as in (6) 
 
𝐽൫𝜑ොሺ𝑘ሻ൯ ൌ ‖∆𝑦ሺ𝑘ሻ െ 𝜑ොሺ𝑘ሻ ∆𝑢ሺ𝑘 െ 1ሻ‖ଶ ൅ 𝜇 ‖𝜑ොሺ𝑘ሻ െ 𝜑ොሺ𝑘 െ 1ሻ‖ଶ 
  ሺ6ሻ 
  
where 𝜇 ൐ 0 is a weighing factor.  
 By minimizing the objective function (6) with respect to 
𝜑ෝሺkሻ,  estimated unknown PPD ሺ𝜑ොሺ𝑘ሻሻ is found as follows:  
 
𝜑ොሺ𝑘ሻ ൌ 𝜑ොሺ𝑘 െ 1ሻ ൅  𝜂 ∆𝑢ሺ𝑘 െ 1ሻ ሺ∆𝑦ሺ𝑘ሻ െ 𝜑ොሺ𝑘 െ 1ሻ ∆𝑢ሺ𝑘 െ 1ሻሻ𝜇 ൅ ‖ ∆𝑢ሺ𝑘 െ 1ሻ‖ଶ  
  ሺ7ሻ 
𝜑ොሺ𝑘ሻ ൌ 𝜑ොሺ1ሻ, 𝑖𝑓 |𝜑ොሺ𝑘ሻ| ൑ 𝜀 𝑜𝑟 ∆𝑢ሺ𝑘 െ 1ሻ ൑ 𝜀 
 𝑜𝑟 𝑠𝑖𝑔𝑛ሺ𝜑ොሺ𝑘ሻሻ ് 𝑠𝑖𝑔𝑛ሺ𝜑ොሺ1ሻሻ   
  ሺ8ሻ 
 
where 𝜂 𝜖 ሺ0,1ሿ  is a step constant which is added to make (7) 
more general and flexible, 𝜑ෝሺ1ሻ is the initial value of 𝜑ෝሺ𝑘ሻ and 
𝜀 is a very small positive constant. The reset algorithm (8) is 
employed to make a stronger ability in estimating the time-
varying parameter by the parameter estimation algorithm [16]. 
MFAC is dependent on following four assumptions:  
Assumption 1: The partial derivative of 𝑓ሺ… ሻ in (2) with 
respect to the ሺ𝑛௬ ൅ 2ሻ𝑡ℎ variable is continuous.  
Assumption 2: (2) satisfies the generalized Lipschitz condition. 
Assumption 3: For a given bounded desired output signal 
y∗ሺk ൅ 1ሻ, there exists a bounded control input 𝑢∗ሺ𝑘ሻ such that 
the system output reaches to the y∗ሺk ൅ 1ሻ.  
Assumption 4: The sign of PPD 𝜑ෝሺ𝑘ሻ is assumed to unchanged. 
Nonlinear system (2) satisfying assumption 1, 2, 3 and 4 is 
controlled by (5), (7) and (8) for a regulation problem; i.e.,  
y∗ሺk ൅ 1ሻ ൌ y∗ ൌ 𝑐𝑜𝑛𝑠𝑡, then there exists a constant 𝜆௠௜௡ such that [17]:  
1. 𝑢ሺ𝑘ሻ and 𝑦ሺ𝑘ሻ are bounded and the closed loop system 
is bounded input, bounded output (BIBO) stable.  
2. The tracking error converges monotonically; i.e., 
lim௞→ஶ|y∗ െ yሺk ൅ 1ሻ| ൌ 0    
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D. Different patient conditions and scenarios 
The MFAC controller was subject to a range of inter- and 
intrapatient variations for evaluation. In order to simulate these 
variations, some of the cardiovascular model parameters from 
TABLE I were changed from -20% to +20% of their nominal 
values to create 100 different patient conditions in each of six 
patient scenarios. To identify which parameters to vary, 
sensitivity analysis was used to find which model parameters 
had the greatest effect on the control tracking performance, 
defined in (9), in each patient scenario. The tracking 
performance derived under PID control was calculated in each 
simulation. 
 𝑆𝐴𝐸 ൌ ෍|𝐿𝑉𝐸𝐷𝑃ௗ െ 𝐿𝑉𝐸𝐷𝑃௠|
௡
௜ୀଵ
 ሺ9ሻ 
where 𝐿𝑉𝐸𝐷𝑃ௗ is desired output (target), 𝐿𝑉𝐸𝐷𝑃௠ is model output (measured output), SAE is the sum of absolute error and 
n is number of samples.  
Afterward, dimensionless parameter sensitivity coefficient 𝑆௝ 
was evaluated in each of the six patient scenarios using (10).  
 
 𝑆௝ ൌ 𝜃௝ 𝛥𝐹𝐹଴ 𝛥𝜃௝ 
  ሺ10ሻ 
where 𝐹଴ is the initial nominal value of the objective function in (9), 𝜃௝ is the value of parameter from its baseline, Δ𝐹 is the 
difference between objective function derived by perturbed 
parameter and 𝐹଴ , and Δ𝜃௝ is the difference between value 
perturbed parameter and 𝜃௝. The higher the sensitivity 
coefficients 𝑆௝, the greater the effect that parameter has on 
control tracking performance.   
Sensitivity analysis was performed for the six common 
patient scenarios used to evaluate the MFAC. These scenarios 
were simulated by changing vascular resistance, heart rate and 
reservoir volume. These scenarios were rapid Rpa changes 
(increasing and decreasing), rapid Rsa changes (increasing and 
decreasing), transition from rest to exercise and a passive 
postural change (similar to a head-up tilt) experiment [13]. The 
simulation conditions for each scenario are shown in TABLE 
II. In transition from rest to exercise and passive postural 
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Fig. 5. Comparison of SAE of MFAC and PID controller in different 
scenarios via box plot, the central mark (red line) shows the median, and 
the bottom and top edges (blue lines) of each box show the 25th and 75th 
percentiles. The whiskers extend to the most extreme data points not 
considered outliers, and the outliers are plotted individually using the '+' 
symbol. (a) rising Rsa (1300 to 600 dyne.s.cm-5) and falling Rsa (1300 to 
2600 dyne.s.cm-5) (b) rising Rpa (100 to 40 dyne.s.cm-5) and falling Rpa 
(100 to 500 dyne.s.cm-5) (c) transition from rest to exercise and passive 
postural change. 
(a) 
TABLE II 
SIX DIFFERENT PATIENT SCENARIOS AND THEIR SIMULATION CONDITIONS 
Patient scenarios Simulation conditions Reference 
Increasing Rpa changes 100 to 500 dyne.s.cm-5 [13] 
Decreasing Rpa changes 100 to 40 dyne.s.cm-5 [13] 
Increasing Rsa changes 1300 to 2600 dyne.s.cm-5 [13] 
Decreasing Rsa changes 1300 to 600 dyne.s.cm-5 [13] 
Transition from rest to 
exercise 
1. Increasing heart rate from 60 to 80 bpm 
2. Decreasing Rpa from 100 to 40 
dyne.s.cm-5 
3. Decreasing Rsa from 1300 to 670 
dyne.s.cm-5 
4. Adding 500 mL fluid from a reservoir 
into the heart via the right atrium 
[13] 
Passive postural change Removing 300 mL fluid from the heart into a reservoir [13] 
TABLE III 
SIMULATION OF  INTERPATIENT AND INTRAPATIENT VARIATIONS VIA 
CHANGING THE MOST EFFECTIVE PARAMETERS IN EACH SCENARIO 
Patient scenarios Most effective parameters 
Rpa increase Eesrvf, Esa, Esv, Evc, Rsv, Rmt, Vusv, Vupu, Vusa, Vusv, Vuvc, Vtotal, λlvf and λrvf 
Rpa decrease Eesrvf, Eesra, Esv, Rsv, Vusv, Vtotal, λra and λrvf 
Rsa increase Esa, Vusv, Vtotal and λrvf 
Rsa decrease 
Eeslvf, Eesrvf, Eesra, Esa, Esv, Evc, Rsv, V0lvf, 
Vdlvf, Rmt, Vusv, P0lvf, P0rvf, Vtotal, λlvf, λra and 
λrvf 
Transition from rest to 
exercise 
Eeslvf, Eesrvf, Eesla, Eesra, Esv, Evc, Rsv, V0lvf, 
Rmt, Vusv, Vtotal, λla, λra and λrvf 
 
Passive postural change Eeslvf, Eesrvf, Esv, Evc,  Rsv, V0lvf, Vdlvf, Rmt, Vusv, P0lvf, Vtotal, λla, λlvf and λrvf 
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change scenarios, each parameter is varied using a first order 
system with a time constant of 10 (s) which simulates the 
response of the native circulatory system. The other scenarios 
are simulated to change the Rpa and Rsa in rapid mode (step 
change). If a controller can respond properly to these extreme 
scenarios, it is assumed the controller can also respond to mild 
changes appropriately [13]. 
In each scenario, parameters were deemed significant if the 
sum of the sensitivity coefficient for both +20% and -20% 
parameter variations was at least 0.45. 
E.  MFAC Evaluation 
In order to evaluate the PID and MFAC reponses across 
interpatient and intrapatient variations, a suite of simulated 
LVAD patients were created for each of the six scenarios 
(totaling 600 “patients”). To create each patient, the most 
significant of the 43 cardiovascular model parameters (as 
determined by the results of the sensitivity analysis) were 
randomly changed between -20% to 20% from their nominal 
values.  
In each patient for each scenario, an MFAC control system 
was developed to maintain LVEDP at a constant value, 
according to the following protocol. In the first 100 seconds, the 
heart pump works in a constant speed mode (2400 rpm) which 
allows the cardiovascular system to reach steady state. From 
time 100 sec, the MFAC was activated. At this point, if the 
measured LVEDP is between 3 mmHg to 15 mmHg, the initial 
set point is chosen as 0.2 mmHg greater the current value of 
LVEDP. This enables a simple step response to be evaluated. 
150 seconds after commencement, one of the six patient 
scenarios were simulated. This process was repeated for a 
system controlled with PID control. PID gains with an anti-
windup mechanism were tuned using a quasi-Newtonian 
optimization algorithm to minimize (9) as the same approach 
provided in [11]. The PID parameters were 𝑘௣ ൌ 133.09, 𝑘௜ ൌ
17.17, 𝑘ௗ ൌ 10.21. The MFAC parameters were chosen empirically as 𝜇 ൌ  0.1, 𝜆 ൌ 0.1, 𝜌 ൌ 1, 𝜂 ൌ 1, 𝜑ሺ1ሻ ൌ 0.001 
and 𝜀 ൌ 10ିସ.  
To assess the difference between PID and MFAC 
performance, the sum of absolute error between desired 
LVEDP and measured LVEDP defined in (9) was employed to 
compare the two controllers. Wilcoxon’s test was performed to 
compare the SAE of PID and MFAC across the 100 simulated 
patients for each scenario, with a p-value less than 0.05 
considered significant. Additionally, the number of scenarios in 
which pulmonary congestion occurred was noted. Based on the 
normal range of measured LVEDP (3 to 15 mmHg) [23], 
pulmonary congestions was defined the measured LVEDP 
above 15 mmHg. All values are expressed as mean ± standard 
deviation unless otherwise stated. 
III. RESULTS 
A. LVEDP Detection 
TABLE IV shows the result of the developed real-time LVEDP 
detection in six different patient scenarios (rising and falling 
Rpa, rising and falling Rsa, rest to exercise and postural change) 
for 100 different patient conditions in each case. The results 
show that in all scenarios (600 simulations) with different levels 
of white noise, the developed LVEDP detection method has a 
very small latency (31.62±12.67 ms) for all simulations. 
Accuracy of LVEDP detection method was assigned by 
calculating of mean and standard deviation of the absolute error 
between the actual and detected LVEDP with different level of 
noises in each scenario shown in TABLE IV. The accuracy of 
the developed method for all the simulations is 0.71±0.61 
mmHg.   
B. Sensitivity Analysis     
The result of the sensitivity analysis performed by variation 
of each 43 parameters in six patient scenarios (TABLE III) 
shows that the cardiovascular model parameters total blood 
volume (Vtotal), systemic vein unstressed volume (Vusv), RV end 
diastolic stiffness coefficient (λrvf), systemic vein elastance 
(Esv), RV end systolic elastance (Eesrvf), systemic vein resistance 
(Rsv) have the most impact on the control tracking performance 
in all the patient scenarios (whole results omitted due to space 
limitations on the manuscript but was added as supplementary 
materials in TABLE VI). These parameters were therefore 
varied to simulate the 100 patients for each scenario.  
C. MFAC Evaluation 
As can be seen from Fig. 4, MFAC responds faster to patient 
changes, resulting in a smaller SAE than PID (solid red line 
compared to dash-dot blue line). Futhermore, in three 
simulations out of 100 simulations in transition from rest to 
exercise, PID conroller led to transient pulmonary congestions; 
however, MFAC could prevent pulmonary congestion due to 
the lower peak on the measured LVEDP in those three 
simulations.  
TABLE IV 
EVALUATION OF LVEDP DETECTION 
Scenarios 
Total number of 
simulations in each 
scenario (number 
of cardiac cycles in 
each simulation) 
White noise 
variance 
(mean of 
SNR) 
Accuracy of 
developed 
method 
(mean ± std) 
Latency of  
developed 
method ms 
(mean ± std) 
Rising Rpa 
100 different 
patient conditions 
(190) 
0 (NaN)  0.32 ± 0.10 31.11 ± 4.98 
1 (30.11)  0.38 ± 0.34 32.65 ± 9.87 
2 (24.11) 0.64 ± 0.55 33.20 ± 14.61 
3 (20.60) 0.93 ± 0.75 32.03 ± 15.76 
4 (18.14) 1.27 ± 0.98 30.69 ± 16.45 
Falling Rpa 
100 different 
patient conditions 
(190) 
0 (NaN) 0.36 ± 0.08 30.02 ± 0.36 
1 (31.53) 0.41 ± 0.32 32.31 ± 7.66 
2 (25.52) 0.63 ± 0.54 33.86 ± 13.19 
3 (22.01) 0.91 ± 0.73 33.65 ± 15.20 
4 (19.53) 1.22 ± 0.96 32.60 ± 16.45 
Rising Rsa 
100 different 
patient conditions 
(190) 
0 (NaN) 0.39 ± 0.31 29.24 ± 6.78 
1 (30.31)  0.41 ± 0.44 30.99 ± 9.80 
2 (24.32) 0.62 ± 0.59 31.98 ± 14.20 
3 (20.84) 0.89 ± 0.77 31.74 ± 16.16 
4 (18.40) 1.18 ± 0.97 30.76 ± 17.00 
Falling Rsa 
100 different 
patient conditions 
(190) 
0 (NaN) 0.39 ± 0.07 29.02 ± 2.57 
1 (30.67) 0.40 ± 0.31 30.74 ± 8.18 
2 (24.66) 0.62 ± 0.50 32.16 ± 13.11 
3 (21.16) 0.90 ± 0.72 31.66 ± 14.79 
4 (18.68) 1.23 ± 0.97 30.75 ± 15.83 
Rest to 
Exercise 
100 different 
patient conditions 
(217) 
0 (NaN) 0.41 ± 0.08 29.04 ± 2.15 
1 (31.23) 0.44 ± 0.40 31.27 ± 10.23 
2 (25.22) 0.67 ± 0.63 32.83 ± 15.06 
3 (21.71) 0.94 ± 0.81 32.56 ± 16.37 
4 (19.24) 1.26 ± 1.02 31.41 ± 16.75 
Postural 
Change 
100 different 
patient conditions 
(190) 
0 (NaN) 0.38 ± 0.08 30.36 ± 2.36 
1 (31.34) 0.40 ± 0.30 32.18 ± 7.66 
2 (25.33) 0.63 ± 0.54 33.43 ± 12.89 
3 (21.83) 0.90 ± 0.72 33.05 ± 14.85 
4 (19.35) 1.22 ± 0.97 32.07 ± 15.98 
IEEE Transactions on Biomedical Engineering, http://dx.doi.org/10.1109/TBME.2019.2932233                                                                 7 
 
 
Fig. 5 shows the comparison of SAE of MFAC and PID 
control for all patients in all scenarios. From the figure, in four 
patient scenarios (decreasing Rpa, increasing Rsa, rest to exercise 
and postural change), SAE (mmHg) derived from MFAC are 
much less than SAE from PID control (3989.48±700.84 and 
5869.55±1157.66 for Rpa decrease, and  6608.90±830.94 and 
10841.26±1745.66 for Rsa increase, 7353.51±1165.62 and 
16948.92±4104.39 for rest to exercise, and 2945.74±403.39 
and 3330.475±428.37 for postural change corresponding to 
MFAC and PID controller respectively). In two other scenarios 
(increasing Rpa and decreasing Rsa) SAE (mmHg) derived from 
MFAC is almost similar or better than the PID controller 
(80270.31±23575.38 and 80087.31±23356.09 for Rpa increase, 
and 11715.23±5161.54 and 31687.86±9183.17 for decrease Rsa 
corresponding to MFAC and PID controller respectively). 
Mean and standard deviation of the SAE for all the 600 
simulations are 18813.86±29345.78 and 24794.22 ± 28380.48 
corresponding to MFAC and PID controller respectively.  
TABLE V demonstrates the statistical result of the 
Wilcoxon’s test in comparison of MFAC and PID controller for 
different patient conditions. In four out of six patient scenarios 
(decreasing Rpa, increasing Rsa, rest to exercise and postural 
change) the p-values are less than 0.05, indicating that MFAC 
has better performance than PID control.  
IV. DISCUSSION 
One of the key issues of current physiological control 
systems [10]–[13], [15] is that they have been simulated in very 
specific conditions for single patient scenarios. This is not 
realistic, as each patient’s cardiovascular system dynamics vary 
throughout the day and are unlikely to be identical to another 
patient. We argue that the control systems evaluated against a 
single simulated patient cannot be guaranteed to be robust 
against a wide patient cohort. The use of single-patient 
evaluation may also be another reason for the popularity of 
simple linear PID control in LVAD control systems [8]–[11]. It 
has yet to be established how simple PID control fares in the 
context of a wider patient suite.  
In this study, we compared linear PID control and MFAC 
across a range 600 randomized patient scenarios. The results 
indicate that MFAC offers either similar or consistently better 
performance across all scenarios when compared to PID 
control. This indicates that the previous evaluation techniques 
were remiss in not considering the effect of plant variation on 
control system performance.  
The results from Fig. 5 and TABLE V show that MFAC can 
improve the tracking performance compared to PID control 
since MFAC adjusts its parameters adaptively only based on the 
input/output data of the cardiovascular system. In fact, MFAC 
parameters were automatically changed by interpatient and 
intrapatient variations and any unpredicted changes on 
hemodynamics can be responded by MFAC due to the adaptive 
structure of the controller. There is also a mathematical proof 
that confirms the error between desired and measured output 
converges to zero by using the MFAC method. The lower SAE 
on control tracking performance means the measured LVEDP 
follows the desired LVEDP in the range of 3 to 15 mmHg faster 
and with less amplitude oscillations leading to fewer ventricular 
suctions and pulmonary congestion events. From the results it’s 
clear that in the four patient scenarios (increasing Rsa, rest to 
exercise, decreasing Rpa and postural change) MFAC control 
tracking performance is much better compared to PID 
controller, in the other two scenarios (increasing Rpa and 
decreasing Rsa) SAE derived from MFAC is not significantly 
different than compared to PID. Optimization of finding the 
MFAC parameters can lead to further improvement in control 
tracking performance compared to the optimized PID 
controller. 
Another advantage of MFAC over PID is that tuning and 
optimization of PID controllers must be performed offline by a 
control engineer. If the performance is unsatisfactory, a control 
engineer familiar with the cardiovascular system may be 
required to make adjustments, as clinicians don’t have the 
specialist engineering knowledge to make these adjustments. 
On the other hand, MFAC just uses the real-time measurement 
I/O data of the controlled system to self-adjust its parameters 
and so no additional input is required. Clinicians can therefore 
focus on treating their patient and not worry about 
underperforming or unstable control systems. 
Although an adaptive physiological controller of rotary 
blood pumps using intrinsic pump parameters on two different 
pumps was proposed by Wu [24], it was based on a linear state-
space model of cardiovascular system. This approach is 
difficult to  use for simulation of different patient conditions, as 
the  model linearization may not be constant across the suite of 
patients. This may lead to inaccuracy of simulation and 
therefore inconsistent control performance. Furthermore, the 
pump flow derived from feedback signals of intrinsic pump 
parameters was assumed to be the total flow to the human 
circulation system, which increases the estimation error of 
aortic pressure [24]. In addition, there was no methodology to 
prevent the possible suction and congestion events [24]. 
However, in this study, a stable model-free adaptive controller 
was employed to provide guaranteed controller performance 
across a range of 600 different patient conditions (six different 
scenarios), preventing suction and congestion events. In 
addition, the MFAC controller doesn’t have the common issues 
of other model-free adaptive controllers like ANN and Fuzzy 
controllers (i.e. difficulty to collect training data and finding the 
rules). Model predictive controllers and optimal controllers 
require a simplified and generalized state-space model that 
cannot be modified for different patients’ conditions.  
TABLE V 
RESULTS OF THE WILCOXON’S TEST IN COMPARISON OF MFAC AND PID FOR 
DIFFERENT PATIENT SCENARIOS 
Scenarios p-value 
Increasing Rpa 0.9542 
Decreasing Rpa 0.0198 
Increasing Rsa 1.7067e-06 
Decreasing Rsa 0.0998 
Rest to exercise 9.9469e-28 
Postural change 1.5741e-10 
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As reported in the literature [10]–[12], Starling-like 
controllers have been proposed to restore Frank-Starling 
response of the native heart. One of the issues with the Frank-
Starling mechanism is that the desired flow for Frank-Starling 
curve must be set manually by clinicians for each patient. As 
there is no automatic procedure on finding the Frank-Starling 
curve without clinical check-up, employing Starling-like 
controller for different patient conditions is impossible. In order 
to minimize clinical check-up and find an automatic procedure 
to set desired flow or LVEDP, constant LVEDP scheme was 
used in this study to maintain LVEDP in the range of 3 mmHg 
to 15 mmHg for each patient (to prevent ventricle suction and 
pulmonary congestion). This can be an appropriate way to 
respond to the interpatient and intrapatient variations.    
The evaluation of the developed LVEDP detection in 
TABLE IV shows that the proposed method can identify the 
end-diastolic pressure across a range of different levels of noise 
with very low delay in a real-time mode. To the author’s 
knowledge, there are no other LVEDP detection methods like 
this. Other investigators have previously addressed this by 
utilizing the minimum left ventricular pressure, which is not a 
realistic measure of preload in the ventricle [11]. The LVEDP 
detection method proposed in this paper will enable robust 
detection of LVEDP for physiological control, improving the 
performance of physiological control systems. 
This study has some limitations. The first limitation is that 
our developed methodology hasn’t employed the Frank-
Starling mechanism to balance systemic and pulmonary flow. 
Frank-Starling-like controllers setting flow rate as a function of 
preload have been developed in [9], [19], and shown to be one 
of the best performing physiological control systems [13]. 
However, finding the Frank-Starling function for each different 
patient with various conditions is difficult. Therefore, to 
simplify the controller, LVEDP was maintained as a constant 
value in the range between 3 mmHg to 15 mmHg. 
Second, the baroreflex was not simulated in this study which 
may influence performance and hemodynamics [25]. However, 
the MFAC controller can compensate its impact properly since 
any changes due to the baroreflex can be interpreted as a 
nonlinearity like to a different patient condition or scenario. 
 Third, this study assumes the left ventricular pressure can be 
measured. However, currently, there are no commercial long-
term implantable pressure sensors. Alternatively, the pressure 
sensor can be replaced by pressure estimation algorithms which 
have been used in several original implementations of evaluated 
control systems like that for constant pump flow [7]. Further 
investigation is required to determine if the developed 
physiological control system can use pressure estimation 
algorithms instead of sensors [26]–[28]. 
Fourthly, this study was completed in-silico. Most LVAD 
physiological control systems are evaluated on the bench top 
using mock circulation loops, to verify numerical model 
findings. However, the numerical model used in this study was 
extensively validated using animal data. Additionally, the 
numerical model is easily scalable: it enabled us to easily 
simulate 600 patient conditions across 6 different scenarios. 
This is a laborious process to conduct using bench top testing. 
Future work will involve validating this system on the bench 
top and in-vivo.   
Fifthly, this study used a model of the VentrAssist LVAD. 
The VentrAssist is no longer used clinically, however as it is a 
centrifugal pump like the commonly used HeartWare HVAD 
(Medtronic Inc., FL, USA), it is hypothesized that there would 
be little difference in performance. Future work will involve 
repeating this experiment using models of clinically available 
pumps. 
 Finally, pathological states of the heart may drastically alter 
left ventricular pressure waveform shapes. Future work will 
include adding pathological states to the numerical heart failure 
model. 
Controlling LVEDP at the expense of aortic pressure or 
inappropriate LVAD flow that could result in thrombogenesis 
or hemolysis also needs to be taken into consideration. Future 
work will involve developing an adaptive target for LVEDP 
that considers both arterial pressure and flow rate. 
V. CONCLUSION 
In this study, a novel physiological control for an implantable 
heart pump has been developed to respond to interpatient and 
intrapatient variations to maintain the LVEDP in the normal 
range of 3 to 15 mmHg to prevent ventricle suctions and 
pulmonary congestions. A new algorithm was developed to 
detect LVEDP from pressure sensor measurement in real-time 
mode. Interpatient and intrapatient variations have been 
simulated based on sensitivity analysis, in which the most 
effective parameters of CVS have been determined by changing 
the CVS parameter between -20% to +20 of their nominal 
values. Tracking controller performance has been assessed via 
simulation of 100 different patient conditions in each of six 
different patient scenarios showing the preference of MFAC 
compared to PID control reducing the risk of suction and 
congestion events in patients. 
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